David Protein Says ‘Diet’ Trends Are Over, GLP-1s Upend Markets
David Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
Shifting funds with limited resources requires thoughtful prioritization. This intro provides practical tips to optimize your remaining dollars.
25,048 articlesDavid Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
A nationwide lettuce recall disrupts menus and weighs on restaurant margins. Investors watch producers and chains as ...
Traditional media is fading as a pillar of democratic information, pushing investors to rethink exposure and resilien...
February brought a sharp pullback for Robinhood, driven by crypto swings and a broader shift in its business model. T...
This week brought a sharp 19% drop in first majestic silver corporation shares. In this article, we break down the ma...
Trump’s move to bring Elon Musk into a China diplomacy frame marks a dramatic shift for investors. The pairing could ...
Eli Lilly has been a standout growth stock thanks to GLP-1 drug demand. Could a stock split be on the horizon? This g...
A growing number of high-earning savers say they’ve reached their retirement targets but can’t walk away from work. A...
A new industry view reframes AI as a productivity boost that reshapes tasks, not a job killer, while Gen Z markets fi...
Nvidia’s 2026 story isn’t all hype. This guide explains why the stock is under pressure, the role of the Magnificent ...
The monthly nonfarm payrolls report is a big market event, but it can mislead if you lean on it without guarding agai...
The inaugural Fortune-style Crypto 40 lays out who truly moves the crypto economy in 2026, led by Uniswap in DeFi and...